Clinical Trial Update: Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting safety and tolerability of the methylphenidate transdermal system (MTS) in children aged 6-12 with ADHD previously treated with e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Methylphenidate Transdermal System (Daytrana) (methylphenidate transdermal system)

Snippet

Sponsor: Noven Therapeutics | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED